# REGEND001 Autologous Basal Layer Stem Cell Transplantation for Interstitial Lung Disease (ILD): A Translational Application Study

> **NCT06998706** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Interstitial Lung Disease (ILD)

## Interventions

- **BIOLOGICAL:** REGEND001 Autologous Basal Layer Stem Cell Suspension

## Key facts

- **NCT ID:** NCT06998706
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-30
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06998706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06998706, "REGEND001 Autologous Basal Layer Stem Cell Transplantation for Interstitial Lung Disease (ILD): A Translational Application Study". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06998706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*